Biotech · Private company
SillaJen, Inc.
Track this companyFree. Adds SillaJen, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- Pexastimogene Devacirepvec (Pexa Vec)Phase 3 · Hepatocellular Carcinoma (HCC)ClinicalTrials.gov · fetched Nov 12, 2026
- SorafenibPhase 3 · Hepatocellular Carcinoma (HCC)ClinicalTrials.gov · fetched Nov 12, 2026
- CemiplimabPhase 2 · Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Pexastimogene Devacirepvec (Pexa-Vec)Phase 2 · Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- BAL0891Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- TislelizumabPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaPHASE1 · RECRUITING · started Dec 14, 2022ClinicalTrials.gov NCT05768932 · fetched Nov 12, 2026
- A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell CarcinomaPHASE1_PHASE2 · COMPLETED · started Jun 19, 2018ClinicalTrials.gov NCT03294083 · fetched Nov 12, 2026
- Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib AlonePHASE3 · COMPLETED · started Oct 1, 2015ClinicalTrials.gov NCT02562755 · fetched Nov 12, 2026